MX2014010272A - Derivados del acido fenil alcanoico como agonistas gpr. - Google Patents
Derivados del acido fenil alcanoico como agonistas gpr.Info
- Publication number
- MX2014010272A MX2014010272A MX2014010272A MX2014010272A MX2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- phenyl
- methoxy
- halo
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D307/08—Preparation of tetrahydrofuran
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603988P | 2012-02-28 | 2012-02-28 | |
| US201261736622P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/051555 WO2013128378A1 (en) | 2012-02-28 | 2013-02-27 | Phenyl alkanoic acid derivatives as gpr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014010272A true MX2014010272A (es) | 2015-08-14 |
Family
ID=48225087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010272A MX2014010272A (es) | 2012-02-28 | 2013-02-27 | Derivados del acido fenil alcanoico como agonistas gpr. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150072969A1 (enExample) |
| EP (1) | EP2820005A1 (enExample) |
| JP (1) | JP2015508809A (enExample) |
| KR (1) | KR20140138243A (enExample) |
| CN (1) | CN104144920A (enExample) |
| AR (1) | AR090191A1 (enExample) |
| AU (1) | AU2013227266A1 (enExample) |
| CA (1) | CA2866210A1 (enExample) |
| IL (1) | IL234254A (enExample) |
| IN (1) | IN2014MN01839A (enExample) |
| MX (1) | MX2014010272A (enExample) |
| NZ (1) | NZ631569A (enExample) |
| RU (1) | RU2014138894A (enExample) |
| TW (1) | TW201341356A (enExample) |
| WO (1) | WO2013128378A1 (enExample) |
| ZA (1) | ZA201407034B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500585B1 (en) | 2011-09-16 | 2018-09-07 | Sanofi Sa | Aniline derivatives, their preparation and their therapeutic application |
| WO2015028960A1 (en) * | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2015125085A1 (en) | 2014-02-19 | 2015-08-27 | Piramal Enterprises Limited | Compounds for use as gpr120 agonists |
| EP3172185B1 (en) * | 2014-07-25 | 2020-03-04 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| WO2016032120A1 (ko) * | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| KR101641023B1 (ko) | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| EP3191463B1 (en) | 2014-09-11 | 2019-10-30 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| DK3737470T5 (da) | 2018-01-08 | 2024-05-27 | Celon Pharma Sa | 3-phenyl-4-hexynsyrederivater som gpr40-agonister |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PL3820572T3 (pl) | 2018-07-13 | 2024-02-26 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
| CA3117199C (en) | 2018-10-24 | 2024-03-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN114945560B (zh) | 2019-10-07 | 2024-08-13 | 卡尔优普公司 | Gpr119激动剂 |
| CN115667277A (zh) | 2020-02-28 | 2023-01-31 | 卡尔优普公司 | Gpr40激动剂 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2024211164A2 (en) * | 2023-04-03 | 2024-10-10 | Trustees Of Dartmouth College | Fatty acid mimetics as modulators of gpr40 and/or gpr120 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3400392B2 (ja) * | 1994-10-18 | 2003-04-28 | ファイザー製薬株式会社 | ５−リポキシゲナーゼ阻害剤及び新規医薬組成物 |
| SK281577B6 (sk) * | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
| US5883106A (en) * | 1994-10-18 | 1999-03-16 | Pfizer Inc. | 5-lipoxygenase inhibitors |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| CA2393027A1 (en) * | 1999-12-17 | 2001-06-21 | Abbott Laboratories | Inhibitors of interleukin 5 gene expression |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| EP1690538A4 (en) * | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
| BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| KR20080056288A (ko) * | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Ｐｐａｒ 조절제로서의 화합물 및 조성물 |
| AU2007253929B2 (en) * | 2006-05-18 | 2011-07-21 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
| TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| US8030354B2 (en) * | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| RU2527177C2 (ru) * | 2007-12-20 | 2014-08-27 | Энвиво Фармасьютикалз, Инк. | Четырехзамещенные бензолы |
| EP2260017A1 (en) | 2008-03-06 | 2010-12-15 | Amgen, Inc | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| CA2739888C (en) | 2008-10-15 | 2013-11-19 | Amgen Inc. | Spirocyclic gpr40 modulators |
| CN102186825A (zh) * | 2008-10-21 | 2011-09-14 | 麦它波莱克斯股份有限公司 | 芳基gpr120受体激动剂和其用途 |
| EP2356113B1 (de) * | 2008-11-14 | 2015-01-07 | Bayer Intellectual Property GmbH | Heterocyclisch substituierte aryl-verbindungen als hif-inhibitoren |
| AU2010240142A1 (en) | 2009-04-22 | 2011-11-10 | Astellas Pharma Inc. | Carboxylic acid compound |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| EP2453900A1 (en) * | 2009-07-17 | 2012-05-23 | Shire LLC | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| IN2013CN01340A (enExample) | 2010-07-23 | 2015-08-07 | Connexios Life Sciences Pvt Ltd | |
| US9073895B2 (en) * | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
-
2013
- 2013-02-27 NZ NZ631569A patent/NZ631569A/en not_active IP Right Cessation
- 2013-02-27 CA CA2866210A patent/CA2866210A1/en not_active Abandoned
- 2013-02-27 AU AU2013227266A patent/AU2013227266A1/en not_active Abandoned
- 2013-02-27 CN CN201380011377.0A patent/CN104144920A/zh active Pending
- 2013-02-27 KR KR1020147027497A patent/KR20140138243A/ko not_active Withdrawn
- 2013-02-27 JP JP2014559335A patent/JP2015508809A/ja active Pending
- 2013-02-27 TW TW102106971A patent/TW201341356A/zh unknown
- 2013-02-27 MX MX2014010272A patent/MX2014010272A/es unknown
- 2013-02-27 US US14/381,696 patent/US20150072969A1/en not_active Abandoned
- 2013-02-27 WO PCT/IB2013/051555 patent/WO2013128378A1/en not_active Ceased
- 2013-02-27 IN IN1839MUN2014 patent/IN2014MN01839A/en unknown
- 2013-02-27 EP EP13719305.8A patent/EP2820005A1/en not_active Withdrawn
- 2013-02-27 RU RU2014138894A patent/RU2014138894A/ru not_active Application Discontinuation
- 2013-02-28 AR ARP130100630A patent/AR090191A1/es unknown
-
2014
- 2014-08-21 IL IL234254A patent/IL234254A/en not_active IP Right Cessation
- 2014-09-26 ZA ZA2014/07034A patent/ZA201407034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201407034B (en) | 2017-08-30 |
| AU2013227266A1 (en) | 2014-10-02 |
| AR090191A1 (es) | 2014-10-29 |
| CA2866210A1 (en) | 2013-09-06 |
| US20150072969A1 (en) | 2015-03-12 |
| KR20140138243A (ko) | 2014-12-03 |
| NZ631569A (en) | 2016-10-28 |
| IN2014MN01839A (enExample) | 2015-07-03 |
| JP2015508809A (ja) | 2015-03-23 |
| EP2820005A1 (en) | 2015-01-07 |
| RU2014138894A (ru) | 2016-04-20 |
| TW201341356A (zh) | 2013-10-16 |
| IL234254A (en) | 2017-03-30 |
| WO2013128378A1 (en) | 2013-09-06 |
| CN104144920A (zh) | 2014-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014010272A (es) | Derivados del acido fenil alcanoico como agonistas gpr. | |
| AU2021237185B2 (en) | GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same | |
| EP3172185B1 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| JP6095580B2 (ja) | 芳香環化合物 | |
| US10662170B2 (en) | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | |
| WO2013122029A1 (ja) | 芳香環化合物 | |
| WO2014170842A2 (en) | Substituted alkyl carboxylic acid derivatives as gpr agonists | |
| KR102563111B1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
| EP3191463B1 (en) | Fused heterocyclic compounds as gpr120 agonists | |
| KR101942752B1 (ko) | Ｇｐｒ120 효능제로서의 티오아릴 유도체 | |
| US11773077B2 (en) | Compounds containing carbon-carbon linker as GPR120 agonists | |
| RU2800290C1 (ru) | Агонист рецептора glp-1, фармацевтическая композиция, содержащая его, и способ его приготовления | |
| NZ733800B2 (en) | Compounds containing carbon-carbon linker as gpr120 agonists | |
| JP2006527215A (ja) | パラ置換されたフェニルカルバメート |